Related Experiment Video
Updated: Oct 1, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Is there a latent left ventricular dysfunction in hypertensive patients with preserved ejection fraction?
Insights
Early detection of left ventricular dysfunction in hypertension is crucial. Global Longitudinal Strain (GLS) is a sensitive biomarker for subclinical myocardial impairment in hypertensive patients, enabling earlier intervention.
Area of Science:
- Cardiology
- Echocardiography
- Hypertension Research
Background:
- Early detection of left ventricular (LV) dysfunction is vital for reducing cardiovascular morbidity and mortality.
- Hypertension is a major risk factor for developing LV dysfunction.
- Preserved ejection fraction (EF) can mask underlying systolic impairment.
Purpose of the Study:
- To evaluate longitudinal contractility in patients with essential hypertension and preserved LV ejection fraction (EF).
- To detect latent impairment of LV systolic function using advanced echocardiographic techniques.
Main Methods:
- Prospective case-control study involving 121 hypertensive patients and 39 healthy controls.
- Utilized conventional echocardiography and 2D-speckle tracking echocardiography (2D-STE) for imaging.
- Assessed global longitudinal strain (GLS) and diastolic function parameters.
Main Results:
- Hypertensive patients showed increased septal thickness, LV mass, and left atrium volume compared to controls.
- Global Longitudinal Strain (GLS) was significantly reduced in hypertensive patients (-17.69 ± 4.06%) versus controls (-22.70 ± 5.02%).
- A decrease in GLS was more pronounced in hypertensive patients with left ventricular hypertrophy.
Conclusions:
- Global Longitudinal Strain (GLS) is a sensitive biomarker for subclinical myocardial dysfunction in hypertensive patients.
- Identifying patients with impaired GLS can facilitate earlier intervention strategies.
- This approach may help mitigate the risk of heart failure in hypertensive individuals.
Introduction:
Early detection of left ventricular (LV) dysfunction may represent a clinical finding that would justify aggressive treatment aimed to reduce cardiovascular morbidity and mortality.
Aim:
To evaluate longitudinal contractility in patients with essential hypertension and preserved LV ejection fraction (EF), in an attempt to detect latent impairment of LV systolic function.
Methods:
Prospective case-control study carried out on 121 (67 male/54 female) hypertensive patients (HTN group) with preserved EF and without any symptoms of heart failure and 39 age- and gender-matched healthy subjects as a control group. Conventional echocardiographic study, as well as 2D Longitudinal strain imaging by 2D-speckle tracking echocardiography (2D-STE), were performed.
Results:
Mean age of patients was 60,48 ± 10.5 years old. The LV end-diastolic diameter and LVEF were comparable between the two groups. Hypertensive patients had greater septal thickness, left ventricular mass, and maximum left atrium volume (p respectively at 0.02; 0.04; and 0.01). Only 20 patients (16.5%) had left ventricular hypertrophy (LVH). The architecture of LV was normal in 57.8 % (n=70) patients. A statistically significant difference between the two groups was found for all diastolic function parameters except Em /Ea ratio and DTEm. In comparison with normal controls, GLS was significantly attenuated in patients with HTN (-17.69 ± 4.06 % versus -22.70 ± 5.02% in controls (p=0.000) and 67 (55.4%) hypertensive patients had a GLS<-20% (in absolute value). The decrease of GLS was more marked in the hypertensive group with left ventricular hypertrophy.
Conclusion:
The results of our study confirmed that GLS is a sensitive biomarker of subclinical myocardial dysfunction in hypertensive patients, this suggests that identifying patients at higher risk for heart failure and earlier inter¬vention may be beneficial.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Mitral Regurgitation I: Introduction
Heart Failure III: Clinical Manifestations
Mitral Stenosis I: Introduction

